Pediatric Praziquantel Consortium

Pediatric Praziquantel Consortium: Successful annual Access meeting

30 March 2020

Last month, ahead of the COVID-19 crisis in Europe, the Pediatric Praziquantel Consortium Access team gathered in...

The Pediatric Praziquantel Consortium supports first ever World Neglected Tropical Diseases Day

28 January 2020

This Thursday, 30 January, marks the inaugural World Neglected Tropical Diseases (NTD) Day, an initiative created to...

A new formulation to fight Schistosomiasis

A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund


Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more